ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Friday, November 6, 2020

9:00AM-11:00AM: Abstract Number: 0009

Prevalence of Hydroxychloroquine and Chloroquine Side Effects in Rheumatology Patients: A Retrospective Survey of 115 Cases

Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0185

Prevalence of Migraine and Neuropathic Pain in Rheumatic Disease

RA – Diagnosis, Manifestations, & Outcomes Poster I: Multimorbidity

9:00AM-11:00AM: Abstract Number: 0132

Prevalence of Osteoporosis and Fragitlity Fractures Is Not Different Between ACPA Positive Patients Compared to ACPA Negative Patients in a Real World Setting, Despite Longer Disease Duration and Glucocorticoid-Treatment

Osteoporosis & Metabolic Bone Disease Poster

9:00AM-11:00AM: Abstract Number: 0081

Prevalence of Systemic Autoimmune Diseases in Polycystic Ovary Syndrome

Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

9:00AM-11:00AM: Abstract Number: 0418

Prevalence of Thyroid Disease Among Patients with Vasculitis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0021

Prioritizing Patient Safety While Maintaining Study Integrity During COVID-19: Lupus Intervention Fatigue Trial Modifications and Lessons Learned

Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0018

PROMIS-29 and Health Related Quality of Life in Rheumatology Outpatients During the COVID-19 Pandemic in New York City

Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0137

PROMIS-29 Scores Are Significantly Higher in Patients with Rheumatoid Arthritis Who Meet Criteria for Co-morbid Fibromyalgia (FM) Than in Those with Rheumatoid Arthritis and No FM

Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

9:00AM-11:00AM: Abstract Number: 0420

Prospective Analysis of the Prevalence of Giant Cell Arteritis in Consecutive Newly Diagnosed Patients with Polymyalgia Rheumatica

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0038

Protein Biomarkers May Differentiate Responders and Non-Responders to Adalimumab, a Tumour Necrosis Factor Inhibitor, in Ankylosing Spondylitis Patients – The Bioefficacy SpA Study

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 0279

Pulmonary Involvement in a Single Center Cohort of Patients with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

9:00AM-11:00AM: Abstract Number: 0006

Race/ethnicity Is Associated with Poor Health Outcomes Amongst Rheumatic Disease Patients Diagnosed with COVID-19 in the US: Data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry

Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0042

Racial and Ethnic Differences in a Multiple Biochemical Measure of Rheumatoid Arthritis Disease Activity

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 0055

Racial and Sex-based Disparities in Health Care Utilization: Eye Inflammation as a Paradigm

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 0227

Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors

RA – Treatments Poster I: RA Treatments & Their Safety

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].